This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Pharmacovigilance Market

Pharmaceutical Advancements Aimed to Curb Chronic Diseases is Scaling Up the Pharmacovigilance Market Growth. FMI Explores Revenue Prospects

Pharmacovigilance Market by Drug Development, Methods, Provider, Geography & region - Forecast 2022 - 2032

Pharmacovigilance Market Outlook (2022-2032)

[315 Pages Report] The pharmacovigilance market is anticipated to increase, from US$ 6.28 billion in 2022 to US$ 24.32 billion in 2032. According to FMI, the market is expected to expand at a CAGR of 13.1% over the course of the projected period.

As a result of the development in chronic illnesses, which necessitates the use of pharmacovigilance more frequently, there is an increased demand for novel pharmaceuticals that are created through meticulous clinical research.

It is anticipated that demand for pharmacovigilance services is likely to increase, as adverse drug reactions (ADRs) happen more frequently. Additionally, a combination of rising expectations for drug safety and rising patient consumption of medications is the main driver of the pharmacovigilance market expansion during the forecast period.

Moreover, clinicians must perform comprehensive tests and data analysis to assure minimal adverse effects, which forces big pharmaceutical companies to work with renowned pharmacovigilance service providers.

Attributes

Details

Pharmacovigilance Market CAGR (2022-2032)

13.1%

Pharmacovigilance Market Size (2022)

US$ 6.28 billion

Pharmacovigilance Market Size (2032)

US$ 24.32 billion

Furthermore, the advent of COVID-19 has given pharmaceutical companies a variety of opportunities to create novel vaccines, resulting in the beginning of multiple clinical trials. This function now makes it easier to enter the pharmacovigilance market, which is the most important stage of any medicine development process.

Therefore, during the anticipated time, the growth of the pharmacovigilance market is likely to be supported by such favorable initiatives.

Customize this Report

Let us know your requirement to get
100% FREE customization

What Strives The Pharmacovigilance Market?

Drivers:

Drivers

As a result of increased public awareness of OTC drug adverse effects; there is a greater need for safer drugs. This feature is anticipated to accelerate the demand for pharmacovigilance due to the monitoring of medications that are readily available on the market for potential adverse drug responses.

Credible information on medicines, their correct usage, side effects, and other topics is transmitted more widely thanks to government initiatives, programs, and pharmaceutical firms' awareness campaigns.

Regarding time restrictions and the facilities that an outsourced service may supply, outsourcing offers clear benefits to manufacturing organizations. Additionally, outsourcing permits businesses to customize services in accordance with their needs, accelerating the evaluation process.

Example:

Example

Every year, the Uppsala Monitoring Centre (UMC) runs a social media campaign to raise patient and public awareness of the importance of reporting suspected ADRs and the safe use of medications.

The American Society of Pharmacovigilance officially launched a national awareness campaign in March 2021 to encourage people who have experienced adverse drug events to share their experiences and foster community support, while praising organizations and healthcare professionals for talking about how they can support medication safety.

On International Patient Safety Day in 2019, Bayer unveiled the SafeTrack digital application, which allows users to report negative incidents. The program is a simple, practical internet tool that enables prompt reporting of an AE.

Lack of Awareness:

Inconsistent reporting is a result of patients' lack of knowledge regarding adverse events (AE). The patient typically becomes worried and reports all of their symptoms as an adverse event (AE). But not all reported adverse events (AEs) are necessarily serious, which forces committees in pharmaceutical firms to make bad decisions that result in the drug's withdrawal.

The necessary software, services, and training are missing in low- and middle-income nations for these specialized services. In addition, little is being done by governments and pharmaceutical firms to raise awareness of AE reporting. The pharmacovigilance market expansion in low- and middle-income nations is predicted to be constrained by these issues.

Data Security:

Moreover, the pharmacovigilance market may see a slowdown during the projected period due to issues like the high risk associated with data security, the absence of global regulatory harmonization, and the lack of data standardization for adverse event collecting.

Comparative View Of Adjacent Pharmacovigilance Market

Pharmacovigilance Market:

Attributes

Pharmacovigilance Market

CAGR (2022-2032)

13.1%

Market Value (2032)

US$ 24.32 billion

Growth Factor

The primary factors driving the market are escalating patient medicine usage and escalating expectations for drug safety.

Opportunity

Government programs, efforts, and pharmaceutical companies' awareness campaigns help spread reliable information about drugs, their proper use, side effects, and other topics, while also creating business opportunities.

Key Trends

While focusing on technology advancement, market participants are constantly creating safety services to promote the acceptance of pharmacovigilance services.

Pharmaceuticals Excipients Market:

Attributes

Pharmaceuticals Excipients Market

CAGR (2022-2032)

6%

Market Value (2032)

US$ 15 billion

Growth Factor

The rapidly expanding pharmaceutical industry and the growing acceptability of orphan drugs are driving up the demand for pharmaceutical excipients.

Opportunity

The pharmaceutical business requires novel functional excipients, which is likely to spur market innovations and boost pharmaceutical excipient sales.

Key Trends

Due to effective strategy, industry leaders regularly release a variety of cutting-edge excipients, as well as modified categories of excipients already on the market.

Pharmaceutical Drug Delivery Market:

Attributes

Pharmaceutical Drug Delivery Market

CAGR (2022-2032)

6%

Market Value (2032)

US$ 3000 billion

Growth Factor

The industry is expanding as a result of leading market participants investing more money in research and development of pharmaceutical drug delivery systems.

Opportunity

Self-administration and home care are expected to offer pharmaceutical medication delivery systems significant future opportunities.

Key Trends

The pharmaceutical medication delivery system has been expanded to include a new class of medicines with huge potential for reducing cancer, diabetes, and other sickness treatments.

Businesses are engaging with one another more regularly due to new platforms like the cloud and social media. As a result, the complexity of attacks, the seriousness of breaches, and potential threats to data security have all increased.

It is crucial for the healthcare industry to protect the proprietary and confidential information linked to services and goods, due to the serious risk of their confidentiality being compromised. Regulatory requirements for conducting clinical trials and post-marketing surveillance are also anticipated to increase demand for pharmacovigilance services during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Segmentation Outlook

Why are Phase-IV Clinical Trials acquiring Importance in Pharmacovigilance Market?

“With a revenue share of more than 75.0% in 2021, the phase IV (post-marketing) segment took the whole market by storm.”

These treatments serve as an extra layer of safety for the medications undergoing clinical trials. Due to intense drug testing on a wide demographic patient base of the highest significance following the commercialization of the drug, it is envisaged that the data gathered and evaluated during this stage is of highest relevance.

Why is Targeted Spontaneous Reporting Attracting Major Investments in the Pharmacovigilance Market?

“In 2021, spontaneous reporting accounted for the biggest share with almost 30%.

This is as the technique is widely used in the detection of novel, severe, and uncommon ADRs and is both effective and affordable. The extensive use of monitoring reports produced using this methodology by the pharmaceutical industry and regulatory bodies is another factor contributing to the segment's rapid expansion.

What is the Regional Analysis of the Pharmacovigilance Market?

  • North America Outlook

North America held the largest revenue share of over 30.0% in 2021 owing to the presence of key pharmaceutical and medical devices players, contributing to the overall revenue in this region. The rising level of drug abuse and associated adverse drug reactions is a leading cause of morbidity and death.

This acts as a high growth rendering factor for the pharmacovigilance market in North America. Rising investment in novel drug development by major players is also anticipated to propel regional market growth.

  • UK Outlook

Currently, a number of clinical trials are anticipated to be carried out to evaluate the effectiveness of different medication candidates, offering up new growth opportunities for UK-based providers of pharmacovigilance solutions.

The London Trials, which are scheduled to start in the summer of 2021, are an example. The Hammersmith Medicines Research organization is managing these trials.

  • Asia Pacific Outlook

Due to the abundance of outsourcing companies, Asia Pacific is anticipated to experience the quickest CAGR of 12.1% during the projection period. Improvements in productivity, cost effectiveness, and resource sharing as a result are predicted to drive up regional demand for pharmacovigilance in the ensuing years.

The regional market is also being driven by expanding investments, rising spending among patients, and supportive government activities for satisfying population needs.

How Are Startups Utilising The Potential In The Pharmacovigilance Market?

Service providers from many regions are developing cutting-edge technologies to support the pharmacovigilance business. Technology comprises real-time products, AI-based solutions, and fresh drugs in the pipeline.

For instance:

  • HEPAprint, a British business, creates predictive software to stop negative medication reactions. The software forecasts the potential effects medications may have on particular genetic markers using artificial intelligence (AI) and individual genetic data.
  • Pharmacovigilance is supported by digital Software-as-a-Service (SaaS) from the German startup MEDIKURA Digital Health. The start-up makes it possible to collect structured data from end users and includes all required parties, including pharmacists, physicians, patients, and manufacturers.
  • AI-based pharmacovigilance solutions are offered by Indian firm Navro Technology Solutions. The business enables pharmaceutical companies to shorten the time required to report adverse drug reactions with the aid of deep learning and AI.
MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

What Is The Competitive Analysis Of The Pharmacovigilance Market?

The patent expiration of branded pharmaceuticals is encouraging new clinical trials to discover new candidates, which is causing prominent companies in the pharmacovigilance market to see an improvement in their revenue prospects. Some market participants use collaborations with top pharmaceutical companies as a key strategy.

Collaboration and Business Services

  • Accenture Plc. and UCB worked together to develop a safety solution based on Accenture's INTIENTTM Pharmacovigilance in December 2019 to utilize artificial intelligence to speed up the process of submitting individual patient safety case reports.
  • Given its significant influence in the pharmaceutical pharmaceuticals sector, Bristol-Myers Squibb (BMS) relocated a portion of its drug safety monitoring operations to India in 2017. Employees of Accenture are now running the pharmacovigilance center.

Key Players

  • Accenture Plc.
  • Bristol-Myers Squibb
  • Clinquest Group B.V.
  • Cognizant Technology Solutions
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc.
  • ICON Plc
  • iGATE Corporation
  • iMED Global Corporation
  • inVentiv Health Inc.
  • Novartis AG
  • PAREXEL International Corporation
  • Pfizer Inc.
  • Pharmaceutical Product Development LLC. (PPD)
  • PRA Health Sciences Inc.
  • Quintiles Transnational Holdings Inc.
  • Sanofi SA
  • Synowledge LLC
  • Wipro Ltd.

Key players like Accenture, Cognizant, and IQVIA are benefiting from improved pharmacovigilance management.

Market players are continuously developing safety services to increase the adoption of pharmacovigilance services, while concentrating on technological progress. Analytics, AI, and automation have increased the effectiveness of the businesses offering pharmacovigilance services. Automation, machine learning, and artificial intelligence are likely to soon lead to a paradigm shift in pharmacovigilance due to their sophisticated technological capabilities.

Cognizant Technology Solutions, which offers a full range of patient safety services, was recently recognized as one of the top businesses in the pharmacovigilance market in April 2021. This follows the company's ongoing efforts to improve its technologically enabled products in order to better assist clients with their digital transformation.

The market is expanding further due to rising R&D and rising adoption of new technologies in clinical research. For instance, industry players like IQVIA and PRA Health Sciences are expected to boost demand in the upcoming years by incorporating virtual services into the clinical trial protocol.

Rising partnerships in the industry between software suppliers and pharmaceutical firms are also anticipated to fuel the demand for pharmacovigilance.

For instance, in November 2021, Deloitte and Sanofi worked together to develop ConvergeHEALTH Safety, a next-generation adverse events case intake platform powered by artificial intelligence (AI). This platform revolutionizes pharmacovigilance and tackles some of the most urgent operational safety issues facing the sector.

Additionally, eco-pharmacovigilance has gained prominence recently and is essential for reducing the likelihood that pharmaceutical pollutants affect the environment. As a result, pharmaceutical firms might use pharmacovigilance services to lessen environmental pollution, fueling the market's expansion.

There is a significant demand for enhanced manufacturing processes, pharmacovigilance, clinical data management, streamlined R & D, and medical writing as a result of the market competition for the introduction of novel compounds. For EUR 1.5 million in 2020, the U.K. government collaborated with the American business Genpact to create an artificial intelligence tool for screening vaccine adverse drug response (ADR) data.

Key segments

By Phase of Drug Development:

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Type of Methods:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

By Service Type Provider:

  • In-house Pharmacovigilance
  • Contract Outsourcing

By Geography:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

The pharmacovigilance market is estimated to record a CAGR of 13.1% during the forecast period.

The pharmacovigilance market size is predicted to be valued at US$ 24.32 billion by 2032.

The pharmacovigilance market share is valued at US$ 6.28 billion in 2022.

North America is the leading region, with a market share of 30.0% in 2021.

The Phase IV segment is the leading segment in the pharmacovigilance market.

Table of Content

1. Introduction

    1.1. Report Description

    1.2. Research Methodology

    1.3. Market Segmentation

2. Executive Summary

3. Global Market Dynamics

    3.1. Introduction

    3.2. Market Drivers

        3.2.1. Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring

        3.2.2. Rise in Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Activities

        3.2.3. Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth

    3.3. Market Restraints

        3.3.1. High Risk Associated with Data Security in Outsourcing

        3.3.2. Lack of Availability of Skilled Labour Might Hinder the Market Growth

        3.3.3. Inadequate System for Herbal Products in Asia Pacific Might Hamper the Market Growth

    3.4. Market Opportunities

        3.4.1. Huge Scope for Rapid Growth of Market in Emerging Economies

        3.4.2. Shift in Preference for Outsourcing among Various Pharmaceutical and Life Sciences Companies

    3.5. Porter’s Five Forces Analysis: Global Market

        3.5.1. Bargaining Power of Suppliers

        3.5.2. Bargaining Power of Buyers

        3.5.3. Threat of Substitutes

        3.5.4. Threat of New Entrants

        3.5.5. Competitive Rivalry

    3.6. Market Attractiveness Analysis: Global Market, by Geography

    3.7. Competitive Landscape

        3.7.1. Market Share Analysis: Global Market, 2014 (Value %)

4. Global Market, by Phase of Drug Development

    4.1. Overview

        4.1.1. Global Market Revenue, by Phase of Drug Development, 2022 - 2032 (US$ Mn)

        4.1.2. Comparative Analysis: Global Market Revenue, by Type of Clinical Trial Phases, 2014(Value %)

    4.2. Preclinical Studies

        4.2.1. Global Preclinical Studies Market Revenue, 2022 - 2032 (US$ Mn)

    4.3. Phase I

        4.3.1. Global Phase I Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

    4.4. Phase II

        4.4.1. Global Phase II Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

    4.5. Phase III

        4.5.1. Global Phase III Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

    4.6. Phase IV or Post Marketing Surveillance

        4.6.1. Global Phase IV Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

5. Global Market, By Type of Methods

    5.1. Overview

        5.1.1. Global Market Revenue, by Type of Method , 2022 - 2032 (US$ Mn)

    5.2. Comparative Analysis: Global Market Revenue, by Type of Method, 2014(Value %)

    5.3. Spontaneous Reporting

        5.3.1. Global Spontaneous Reporting Market Revenue, 2022 - 2032 (US$ Mn)

    5.4. Intensified ADR Reporting

        5.4.1. Global Intensified ADR Reporting Market Revenue, 2022 - 2032 (US$ Mn)

    5.5. Targeted Spontaneous Reporting

        5.5.1. Global Targeted Spontaneous Reporting Market Revenue, 2022 - 2032 (US$ Mn)

    5.6. Cohort Event Monitoring

        5.6.1. Global Cohort Event Monitoring Market Revenue, 2022 - 2032 (US$ Mn)

    5.7. EHR Mining

        5.7.1. Global EHR Mining Market Revenue, 2022 - 2032 (US$ Mn)

6. Global Market, by Type Service Provider

    6.1. Overview

        6.1.1. Global Market Revenue, by Type of Service Provider, 2022 - 2032 (US$ Mn)

        6.1.2. Comparative Analysis: Global Market, by Type of Service Providers, 2014 (Value %)

    6.2. In-house Pharmacovigilance

        6.2.1. Global In-House Market Revenue, 2022 - 2032 (US$ Mn)

    6.3. Contract Outsourcing

        6.3.1. Global Contract Outsourcing Market Revenue, 2022 - 2032 (US$ Mn)

7. Global Market, by Geography

    7.1. Overview

        7.1.1. Global Market Revenue, by Geography, 2022 - 2032 (US$ Mn)

    7.2. North America

        7.2.1. North America Market Revenue, 2022 - 2032 (US$ Mn)

    7.3. Europe

        7.3.1. Europe Market Revenue, 2022 - 2032  (US$ Mn)

    7.4. Asia Pacific

        7.4.1. Asia Pacific Market Revenue, 2022 - 2032 (US$ Mn)

    7.5. Rest of the World (RoW)

        7.5.1. RoW Market Revenue, 2022 - 2032 (US$ Mn)

8. Recommendations

    8.1. Market Strategy

        8.1.1. Strategic Partnerships and Collaborations With CROs And Life Sciences BPOs

        8.1.2. Optimization of Drug Safety Through Hub and Spoke Model

        8.1.3. Developing Operational Activities for Better Outcomes

        8.1.4. Regional Expansion

9. Company Profiles

    9.1. Accenture plc

    9.2. Bristol-Myers Squibb

    9.3. Clinquest Group B.V.

    9.4. Cognizant Technology Solutions

    9.5. Covance, Inc.

    9.6. F. Hoffmann-La Roche Ltd.

    9.7. GlaxoSmithKline plc (GSK)

    9.8. ICON plc

    9.9. iGATE Corporation

    9.10. iMEDGlobal Corporation

    9.11. inVentiv Health, Inc.

    9.12. Novartis International AG

    9.13. PAREXEL International Corporation

    9.14. Pfizer, Inc.

    9.15. Pharmaceutical Product Development, LLC. (PPD)

    9.16. PRA Health Sciences, Inc.

    9.17. Quintiles Transnational Holdings, Inc.

    9.18. Sanofi S.A.

    9.19. Synowledge LLC

    9.20. Wipro Limited

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

TABLE 1: Market Snapshot: Market

TABLE 2: Global Market Revenue, by Phases of Drug Development, 2022 - 2032(US$ Mn)

TABLE 3: Global Market Revenue, by Type of Method, 2022 - 2032(US$ Mn)

TABLE 4: Global Market Revenue, by Type of Service Provider, 2022 - 2032(US$ Mn)

TABLE 5: Global Market Revenue, by Geography, 2022 - 2032(US$ Mn)

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Drug Safety from Molecule to Market

Figure 02: Pharmacovigilance: Market Segmentation

Figure 03: Global Market, by Phase of Drug Development, 2022 (US$ Mn)

Figure 04: Global Market, by Type of Service Provider, 2022 (US$ Mn)

Figure 05: Global Market, by Type of Method, 2022 (US$ Mn)

Figure 06: Comparative Analysis: Global Market, by Geography, 2022 (Value %)

Figure 07: Porter’s Five Forces Analysis: Global Market

Figure 08: Market Attractiveness Analysis: Global Market, by Geography (2022)

Figure 09: Global Market Share Analysis, by Key Player, 2022(%)

Figure 10: Safety Services: Product Lifecycle

Figure 11: Comparative Analysis: Global Market Revenue, by Phase of Drug Development, 2022(Value %)

Figure 12: Global Preclinical Studies Market Revenue, 2022 - 2032 (US$ Mn)

Figure 13: Global Phase I Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

Figure 14: Global Phase II Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

Figure 15: Global Phase III Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

Figure 16: Global Phase IV Clinical Trial Market Revenue, 2022 - 2032 (US$ Mn)

Figure 17: Comparison of Methods: reporting

Figure 18: Comparative Analysis: Global Market Revenue, by Type of Method, 2022 & 2020 (Value %)

Figure 19: Global Spontaneous Reporting Market Revenue, 2022 - 2032 (US$ Mn)

Figure 20: Global Intensified ADR Reporting Market Revenue, 2022 - 2032 (US$ Mn)

Figure 21: Global Targeted Spontaneous Reporting Market Revenue, 2022 - 2032 (US$ Mn)

Figure 22: Global Cohort Event Monitoring Market Revenue, 2022 - 2032 (US$ Mn)

Figure 23: Global EHR Mining Market Revenue, 2022 - 2032 (US$ Mn)

Figure 24: End-to-End Safety Across the Lifecycle

Figure 25: Comparative Analysis: Global Market, by Type of Service Provider, 2022 & 2020 (Value %)

Figure 26: Global In-House Market Revenue, 2022 - 2032 (US$ Mn)

Figure 27: Global Contract Outsourcing Market Revenue, 2022 - 2032 (US$ Mn)

Figure 28: North America Market Revenue, 2022 - 2032 (US$ Mn)

Figure 29: Europe Market Revenue, 2022 - 2032 (US$ Mn)

Figure 30: Asia Pacific Market Revenue, 2022 - 2032 (US$ Mn)

Figure 31: RoW Market Revenue, 2022 - 2032 (US$ Mn)

Figure 32: Accenture, Plc.: Annual Revenue 2022 (US$ Bn)

Figure 33: Bristol-Myers Squibb: Annual Revenue, 2022 (US$ Mn)

Figure 34: Cognizant Technology Solutions: Annual Revenue, 2022 (US$ Mn)

Figure 35: COVANCE, Inc.: Annual Revenue, 2022 (US$ Mn)

Figure 36: F. Hoffmann-La Roche Ltd., Annual Revenue: 2022 (US$ Mn)

Figure 37: GlaxoSmithKline plc (GSK): Annual Revenue, 2022(US$ Mn)

Figure 38: ICON plc.: Annual Revenue, 2022 (US$ Mn)

Figure 39: iGATE Corporation: Annual Revenue, 2022 (US$ Mn)

Figure 40: Novartis International AG: Annual Revenue, 2022 (US$ Mn)

Figure 41: PAREXEL International Corporation: Annual Revenue 2022 (US$ Mn)

Figure 42: Pfizer, Inc.: Annual Revenue, 2022 (US$ Mn)

Figure 43: PRA Health Sciences, Inc., Annual Revenue: 2022 (US$ Mn)

Figure 44: Quintiles Transnational Holdings, Inc.: Annual Revenue, 2022 (US$ Mn)

Figure 45: Sanofi: Annual Revenue, 2022 (US$ Mn)

Figure 46: Wipro Limited: Annual Revenue 2022 (US$ Mn)

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Consumer Product

Pharmaceutical E-commerce Market

Published : June 2022

Healthcare

Pharmacy Refrigerators Market

Published : July 2017

Technology

Pharma and Healthcare Social Media Marketing Market

Published : July 2020

Google translate

Pharmacovigilance Market